Chemoprevention of colorectal cancer

Gut

Volumn 43, Issue 4, 1998, Pages 578-585

  Langman, M ^a   Boyle, P ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CALCIUM; CIMETIDINE; DICLOFENAC; EFLORNITHINE; FOLIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; METIAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOID; RETINOL; SULINDAC; URSODEOXYCHOLIC ACID; VITAMIN; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031691126     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.4.578     Document Type: Review

References (121)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Boyle P, Zaridze DG, Smans M. Descriptive epidemiology of colorectal cancer. Int J Cancer 1985;36:9-18.
3. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality rate from 18 major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
4. Peleg I, Maibach HT, Brown SH, et al. Aspirin and non-steroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
5. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991;83:355-8.
6. Kune GA, Kune S, Watson JF. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-404.
7. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
8. Logan RF, Little J, Hawtin PG, et al. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-9.
9. Narisawa T, Sato M, Tani M, et al. Inhibition of development of methylnitrosourea induced colonic tumours by peroral administration of indomethacin. Gann 1982;73:377-81.
10. Reddy BS, Rao CV, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F 344 rats. Carcinogenesis 1993;14:1493-7.
11. Labayle D, Frischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
12. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-16.
13. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55: 2556-9.
14. Gustafson-Svard C, Lilja I, Hallbook O, et al. Cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996;38:79-84.
15. Eberhart CE, Coffey RJ, Radhika A, et al. Upregulation of cyclo-oxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
16. Oshima M, Dinchuk JG, Kargman S, et al. Suppression of intestinal polyposis Ape. D761 knock out mice by inhibition of cyclo oxygenase 2 (COX-2). Cell 1996;87:803-9.
17. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Ape Min mouse model by the non-steroidal anti-inflammatory drug piroxicam. Cancer Res 1996;56:710-14.
18. Powell SM, Zilz N, Beazer-Barclay Y, et al. Ape mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-7.
19. Piazza GA, Kulchak Rahm AL, Krutzysch M, et al. Anti-neoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-16.
20. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterelogy 1995;109:994-8.
21. Shiff S J, Qiao L, Tsai L, et al. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
22. Tsuji M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
23. Elder DJE, Hague A, Hicks DJ, et al. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumour cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996;56:2273-6.
24. Ladenheim J, Garcia G, Titzor D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-7.
25. Lala PK, Parhar RS, Singh P. Indomethacin therapy abrogates the prostaglandin mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol 1986;99:108-18.
26. Narisawa T, Takahashi M, Masuda T, et al. Prevention of peritoneal carcinoma tosis recurrence with a prostaglandin synthesis inhibitor, indomethacin. Gan To Kagaku Ryoho 1987;14:2496-501.
27. Schultz, RM, Altorn MG. Potentiation of non-specific immunotherapy of experimental lung metastases by indomethacin. J Immunopharmacol 1983; 5:277-80.
28. Weppelmann B, Monkemeier D. The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix. Gynecol Oncol 1984;7:196-9.
29. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
30. Silverstein FH, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-9.
31. Ehsannullah RSB, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
32. Taha A, Hudson N, Hawkey CJ, et al. Famotidine for prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996;334:1435-9.
33. Jansen JBMJ, Klinkenbery-Knol EC, Meuwissen SGM, et al. Effect of long-term treatment with omeprazole on gastric acid and pepsin secretion and fasting serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990;99:621-8.
34. Thorburn CM, Friedman GD, Orentrcich N, et al. High gastrin levels increase risk for colorectal carcinoma [abstract]. Gastroenterology 1996;110: A603.
35. Freston JW, Borch K, Brand SJ, et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. Dig Dis Sci 1995;40:50S-62S.
36. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
37. Gann PH, Manson JE, Glynn RJ, et al. Low dose aspirin and incidence of colorectal tumours in a randomised trial. J Natl Cancer Inst 1993;85:1220-4.
38. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-6.
39. Weil J, Colin Jones D, Langman MJS, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
40. Huang ME. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood 1988;72:567-72.
41. Castaigne S. All trans retinoic acid as a differentiation therapy for acute promyelocytic leukaemia. BMJ 1990;76:1704-9.
42. Kane KF, Langman MJS, Williams GR. Anti-proliferative reponses of two human colon cancer cell lines to vitamin D3 are differentially modified by 9-cis retinoic acid. Cancer Res 1996;56:623-32.
43. Lehmann JM. Retinoids selective for retinoid X receptor pathways. Science 1992;258:1944-6.
44. Stahelin HB, Gey KF, Eichholzer M, et al. Beta-carotene and cancer prevention: the Basel study. Am J Clin Nutr 1991;53(suppl 1):265-9S.
45. Cahill RJ, O'Sullivan KR, Matthias PM, et al. Effects of vitamin antioxidant supplementation on cell kinetics of patients with adenomatous polyps. Gut 1993;34:963-7.
46. Paganelli GM, Biasco G, Brandi G, et al. Effect of vitamin A, C and E supplementation on rectal cell proliferation in patients with colorectal adenomas. J Natl Cancer Inst 1992;84:47-51.
47. Roncucci L, Di Donato P, Carati L, et al. Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Dis Colon Rectum 1993;36:227-34.
48. Ferraroni M, La Vecchia C, D'Avanzo B, et al. Selected micronutrient intake and the risk of colorectal cancer. Br J Cancer 1994;70:1150-5.
49. Willett WC, Hunter DJ. Vitamin A and cancers of the breast, large bowel, and prostate: epidemiologic evidence. Nutr Rev 1994;52:S53-9.
50. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 1994;331:141-7.
51. Omenn GS, Goodman G, Thornquist MD, et al. Effects of combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
52. Hennekens CH, Buring JE. Long term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
53. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group (1994). The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
54. Fanjul AN. Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996;271:23441-6.
55. PingLu X, Fanjul A, Picard N, et al. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat Med 1997;3:686-90.
56. Bunce CM, Mountford JC, French PJ, et al. Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target probably an enzyme of the aldoketoseductase family. Biochim Biophys Acta 1996;1311:189-98.
57. Bussey HJ, De Cosse JJ, Deschner EE. A randomised trial of ascorbic acid in polyposis coli. Cancer 1982;50:1434-9.
58. De Cosse JJ, Miller HH, Lesser ML. Effect of wheat fibre and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst 1989;81:1290-7.
59. McKeown-Eyssen G, Holloway C, Jazmaji V, et al. A randomised trial of vitamins C and E in the prevention of recurrence of colorectal polyps. Cancer Res 1988;48:4701-5.
60. Garland CF, Shekelle RB, Barrett Connor E, et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985;i:307-9.
61. Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eight year prospective study. Lancet 1989;ii:1176-8.
62. Emerson JC, Weiss NS. Colorectal cancer and solar radiation. Cancer Causes Control 1992;3:95-9.
63. Belleli A, Shany S, Levy J, et al. A protective role of 1,25 dihydroxy vitamin D3 in chemically induced rat colon carcinogenesis. Carcinogenesis 1992;13: 2293.
64. Sitrin MD, Halline AG, Abrahams, C, et al. Dietary calcium and vitamin D modulate 1,2 dimethylhydrazine-induced colonic carcinogenesis in the rat. Cancer Res 1991;51:5608-13.
65. Kane KF, Langman MJS, Williams GR. 1,25 dihydroxy vitamin D3 and retinoid X receptor expression in human colorectal neoplasms. Gut 1995;36:255-8.
66. Eisman JA, Barkla DH, Tutton PJM. Suppression of in-vivo growth of human cancer solid tumour xenografts by 1,25 dihydroxy vitamin D3. Cancer Res 1987;47:21-5.
67. Slater SJ, Kelly MB, Taddeo FJ, et al. Direct activation of protein kinase C by 1,25-dihydroxy Vitamin D3. J Biol Chem 1995;270:6639-43.
68. Binderup L, Latini S, Binderup E, et al. 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 1991;42:1569-75.
69. Binderup L, Bramme E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988;37:889-95.
70. Wali RK, Bissonnette M, Khare S, et al. 1,25-dihydroxy-16-ene-23-yne-26, 27-hexafluorocholecalciferol, a non-calcemic analog of 1,25-dihydroxy vitamin D3 inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res 1995;55:3050-4.
71. Kampman E, Giovannucci E, van't Veer P, et al. Calcium, Vitamin D, dairy foods, and the occurrence of colorectal adenomas among men and women in two prospective studies. Am J Epidemiol 1994;139:16-29.
72. Bostick RM, Potter JD, Sellers TA, et al. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. The Iowa Women's Health Study. Am J Epidemiol 1993;137:1302-17.
73. Byrne PM, Freaney R, McKenna MJ. Vitamin D supplementation in the elderly: review of safety and effectiveness of different regimes. Calcified Tissue International 1995;56:518-20.
74. Reshef R, Rozen P, Fireman Z, et al. Effect of a calcium enriched diet on the colonic epithelial hyperproliferation induced by N-methyl-N-nitro-N-nitrosoguanidine in rats on a low calcium and fat diet. Cancer Res 1990;50: 1764-7.
75. Bostick RM, Potter JD, Fosdick L, et al. Calcium and colorectal epithelial proliferation - a preliminary randomised doubled-blinded placebo-controlled clinical trial. J Natl Cancer Inst 1993;85:132-41.
76. Longnecker MP, Martin-Moreno JM, Knekt P, et al. Serum alphatocopherol concentration in relation to subsequent colorectal cancer: pooled data from five cohorts. J Natl Cancer Inst 1992;84:430-5.
77. Bostick RM, Potter JD, McKenzie DR, et al. Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women's Health Study. Cancer Res 1993;53:4230-7.
78. Giovannucci E, Stampfer MJ, Colditz G, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993;85:875-84.
79. Freudenheim JL, Graham S, Marshall JR, et al. Folate intake and carcinogenesis of the colon and rectum. Int J Epidemiol 1991;20:368-74.
80. Bird CL, Swendseid ME, Witte JS, et al. Red cell and plasma folate, folate consumption, and the risk of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 1995;4:709-14.
81. Cravo ML, Mason JB, Dayal Y, et al. Folate deficiency enhances the development of colonic neoplasia in diphenylhydrazine-treated rats. Cancer Res 1992;32:5002-6.
82. 81a Kim YI, Salomon RN, Graeme-Cook F, et al. Dietary folate protects against the development of macroscopic neoplasia in a dose-responsive manner. Gut 1996;39:732-40.
83. Bestor TH. Methylation meets acetylation. Nature 1998;393:311-12.
84. 82a Baron JA, Sandler RS, Haile RW, et al. Folate intake, alcohol consumption, cigarette smoking and risk of colorectal adenomas. J Natl Cancer Inst 1998; 90:57-62.
85. Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993;119: 549-54.
86. 83a Welch GN, Loscalzo J. Homocysteine and atherosclerosis. N Engl J Med 1998;338:1042-50.
87. De Flora S, Astengo M, Serra D, et al. Inhibition of urethan-induced lung tumors in mice by dietary N-acetylcysteine. Cancer Lett 1986;32:235-41.
88. de Vries N, van Zandwijk K, Pastorino U, et al. The Euroscan study trial. Br J Cancer 1991;64:985-9.
89. Earnest DL, Holubec H, Wali RK, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994;54:5071-4.
90. Rodrigues CMP, Kren BT, Steer CJ, et al. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995;109:1835-44.
91. Wali RK, Frawley BP, Hartmann S, et al. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha B11 and -3. Cancer Res 1995;55:5257-64.
92. Tonneson H, Knigge U, Bulow S, et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988;ii:990-2.
93. Matsumoto M. Cimetidine and survival with colorectal cancer. Lancet 1995;346:115.
94. Adams WJ, Morris DL. Short course cimetidine and survival with colorectal cancer. Lancet 1994;344:1768-9.
95. Kumar A. Cimetidine an immuno-modulator. Ann Pharmacother 1990;24: 289-95.
96. Watson SA, Wilkinson LJ, Robertson JR, et al. Effect of histamine on the growth of human gastro-intestinal tumours: reversal by cimetidine. Gut 1993;34:1091-6.
97. 2 antagonists. Anticancer Res 1983;3:7-10.
98. 2 receptor antagonists in gastric cancer patients focus on the lymphoblastogenesis and cytotoxicity of peripheral blood mononuclear ceils. Int J Immunopharmacol 1994;16:9985-93.
99. Colin Jones DG, Langman MJS, Lawson DH, et al. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut 1992;33:1280-4.
100. Hallissey MT, Dunn JA, Baker PG, et al. A prospective randomised trial of cimetidine therapy in gastric cancer: an interim report [abstract]. Gut 1996;37(suppl 3):A93.
101. Liu T, Mokuolo AO, Rao CV, et al. Regional chemoprevention of carcinogen-induced tumours in rat colon. Gastroenterology 1995;109:1167-72.
102. Meyskens FL, Gerner EW. Development of difluoro-methylornithine as a chemoprevention agent for the management of colon cancer. J Cell Biochem 1995(suppl 22):126-31.
103. Singh J, Kulkarric N, Kelloff G, et al. Modulation of azoxymethane induced mutational activation of ras proto-oncogenes by chemopreventative agents in colon carcinogenesis. Carcinogenesis 1994;15:1317-23.
104. Love RR, Carbone PP, Verma AK, et al. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst 1993;85:732-7.
105. Rao CV, Rivenson A, Katiwalla M, et al. Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res 1993;53:2502-6.
106. O'Dwyer PJ, Szarka CE, Yao KS, et al. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventative dithiolethione oltipraz. J Clin Invest 1996;98:1210-17.
107. Schwartz AG, Pashko LL. Cancer chemoprevention with the adrenocortical steroid dehydroepiandrosterone and structural analogs. J Cell Biochem 1993(suppl 17G):73-9.
108. Clark LC, Hixson LJ, Combs GF Jr, et al. Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 1993;2:41-6.
109. Reddy BS, Rivenson A, El Bayoumy K, et al. Chemoprevention of colon cancer by organoselenium compounds and impact of high- or low-fat diets. J Natl Cancer Int 1997;89:506-12.
110. Vanden Brandt PA, Goldbohm RA, van't Veer P, et al. A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. J Natl Cancer Inst 1993;85:224-9.
111. Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 1995;87:497.
112. Nelson RL, Davis FG, Sutter E, et al. Serum selenium and colonic neoplastic risk. Dis Colon Rectum 1995;38:1306-10.
113. Kuo SM. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett 1996;110:41-8.
114. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventative activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20.
115. Singh S, Sheppard MC, Langman MJS. Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut 1993;34:611-15.
116. Calle E, Miracle Mahill HL, et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of post menopausal women. J Natl Cancer Inst 1995;87:517-23.
117. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large bowel cancer. J Natl Cancer Inst 1995;87:1067-71.
118. Zelen M. Are primary cancer prevention trials feasible? J Natl. Cancer Inst 1988;80:1442-4.
119. Morson BC. Gastrointestinal pathology. Oxford: Blackwell Science, 1979
120. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomised comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993;328:901-6.
121. Cali RL, Pitsch RM, Thorson AG, et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum 1993;36:388-93.